Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings
Incyte Corporation (Nasdaq: INCY) today announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis and independent investigators, will be presented at the 2015 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings. These conferences will take place from May 29th June 2nd (ASCO) in Chicago, IL and June 11th 14th (EHA) in Vienna, Austria.
The abstracts to be presented at ASCO and EHA showcase the depth and breadth of our development pipeline in oncology, as well as the success of our collaboration with Novartis, stated Rich Levy, MD, Incytes Chief Drug Development Officer. Incyte is committed to translating R&D excellence into new medicines which can improve patients lives, and these data, including novel:novel combinations from within our portfolio, provide further evidence of our ongoing progress.
Highlighted ASCO Abstracts
Phillips, TJ et al; Interim analysis of a Phase 1 study of INCB040093, a PI3K inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients with relapsed or refractory B-cell malignancies. Sunday, May 31, 8:00-11:30, discussion 16:30-17:45, abstract # 8520
Forero-Torres, A et al; A Phase 1 study of INCB040093, a PI3K inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients with relapsed or refractory classical Hodgkin lymphoma. Sunday, May 31, 08:00-11:30, abstract # 8558
Verstovsek, S et al; Ruxolitinib in polycythemia vera: Follow-up from the RESPONSE trial. Sunday, May 31, 08:00-11:30, abstract # 7087
Chronic myelomonocytic leukemia
Padron, E et al; A multi-institution Phase I trial of ruxolitinib in chronic myelomonocytic leukemia. Sunday, May 31, 8:00-11:30, discussion 11:30-12:45, abstract # 7021
Highlighted EHA Abstracts
Phillips, TJ et al; A Phase 1 study of patients with relapsed or refractory B-cell malignancies treated with a PI3K inhibitor (INCB040093) alone or in combination with a selective JAK1 inhibitor (INCB039110). Friday, June 12; 17:15-18:45, abstract # P326
Forero-Torres, A et al; A Phase 1 study of patients with relapsed or refractory classical Hodgkin lymphoma treated with a PI3K inhibitor (INCB040093) alone or in combination with a selective JAK1 inhibitor (INCB039110). Friday, June 12; 17:15-18:45, abstract # P333
Kiladjian, J-J et al; Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Saturday, June 13; 11:45-12:00, abstract # S447
Verstovsek, S et al; Safety of ruxolitinib in patients with polycythemia vera: Results from the clinical trial program. Saturday, June 13; 17:15-18:45, abstract # P672
Verstovsek, S et al; Effect of Ruxolitinib on Markers of Iron Deficiency: An Analysis of the RESPONSE Trial. Saturday, June 13; 17:15-18:45, abstract # P673
Griesshammer, M et al; Ruxolitinib provides consistent hematocrit control in patients with polycythemia vera resistant to or intolerant of hydroxyurea. Saturday, June 13; 17:15-18:45, abstract # P670
Passamonti, F et al; Ruxolitinib vs best available therapy in patients with polycythemia vera treated in the RESPONSE study: A subgroup analysis of hydroxyurea- and non-hydroxyurea-treated patients. Friday, June 12, 09:30 to Saturday, June 13, 18:45, abstract # E1334
Harrison, CN et al; Complete hematologic control with ruxolitinib in patients with polycythemia vera resistant to or intolerant of hydroxyurea. Friday, June 12, 09:30 to Saturday, June 13, 18:45, abstract # E1353
Daver, N et al; Ruxolitinib in combination with 5-azacytidine as therapy for patients with myelofibrosis. Saturday, June 13; 12:00-12:15, abstract # S448
Deininger, M et al; Ruxolitinib reduces JAK2617F allele burden in patients with myelofibrosis. Saturday, June 13; 17:15-18:45, abstract # P674
Pilar Giraldo, P et al; Safety and efficacy of ruxolitinib in patients with intermediate-1-risk myelofibrosis from an open-label, multicenter, single-arm expanded access study. Saturday, June 13; 17:15-18:45, abstract # P675
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. For additional information on Incyte, please visit the Companys website at www.incyte.com.
Ruxolitinib is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. Food and Drug Administration, as Jakafi(R) (ruxolitinib), for treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, postpolycythemia vera MF, and postessential thrombocythemia MF.
Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi(R) (ruxolitinib) outside the United States.
Important Safety Information
Jakafi can cause serious side effects, including:
Low blood counts: Jakafi may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you experience unusual bleeding, bruising, fatigue, shortness of breath, or a fever.
Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.
Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.
The most common side effects of Jakafi include: anemia, low platelet count, bruising, dizziness, headache.
These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.
Before taking Jakafi, tell your healthcare provider about all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB), or have been in close contact with someone who has TB, have or had liver or kidney problems, are on dialysis, had skin cancer or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change or stop taking Jakafi without first talking to your healthcare provider. Do not drink grapefruit juice while on Jakafi.
Women should not take Jakafi while pregnant or planning to become pregnant, or if breast-feeding.
Please see the Full Prescribing Information available at www.jakafi.com, which includes a more complete discussion of the risks associated with Jakafi.
Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: the potential efficacy, safety and therapeutic value of Incytes pipeline compounds and the potential of such pipeline compounds and Incytes R&D efforts to produce new medicines and improve patients lives; and Incytes plans to present the enumerated abstract presentations at the 2015 ASCO meeting and the 2015 EHA meeting, as the case may be.
These forward-looking statements are based on the Companys current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the efficacy or safety of Jakafi and the compounds in Incytes pipeline, the results of further research and development, the risks that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards, other market or economic factors, competitive and technological advances, and other risks detailed from time to time in the Companys reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2015. The Company disclaims any intent or obligation to update these forward-looking statements.
Sorry. No data so far.